Clinical Trials Directory

Trials / Completed

CompletedNCT01389141

Age-related Changes in Ovarian Follicular Wave Dynamics

Ovarian Follicular Wave Dynamics During The Menstrual Cycle: Relationship To Age, Reproductive Hormones And Musculoskeletal Health

Status
Completed
Phase
Study type
Observational
Enrollment
70 (actual)
Sponsor
University of Saskatchewan · Academic / Other
Sex
Female
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The investigators hypothesize that age-related changes in the number and growth dynamics of ovarian follicles will be associated with changes in hormone levels and corresponding changes in musculoskeletal health.

Detailed description

The following hypotheses will be tested: 1. Differences in ovarian follicular wave dynamics will be detected in women of different ages; 2. The numbers and patterns of ovarian follicle waves in women are repeatable over multiple menstrual cycles; 3. Differences in inhibin B, inhibin A, and AMH will be detected in women with 2 versus 3 or more follicular waves 4. Differences in FSH, LH, progesterone, inhibin B, inhibin A, and AMH detected in MRA and LRA2 women, will change with the numbers of follicles and waves detected; 5. 'Luteal out of phase events' (aka LOOP cycles) will be more prevalent in LRA2 versus MRA women, and will represent major anovulatory waves and/or ovulatory waves; 6. When compared to MRA group, LRA2 women will have lower bone mineral mass and areal density at the lumbar spine; reduced trabecular density at the distal radius and thinner cortices with lower cortical density at the radial and tibial shaft. Other bone outcomes will be similar between the groups; 7. When compared to MRA group, LRA2 women will have lower total body lean mass, greater fat mass and less dense muscle tissue at the forearm and lower limb and lower hand grip strength. 8. Reduced bone mineral mass, areal density, trabecular density, cortical density and hand grip strength in LRA2 versus MRA women will be associated with reduced follicle number, a greater prevalence of LOOP cycles, higher serum FSH and lower inhibin concentrations

Conditions

Timeline

Start date
2010-02-01
Primary completion
2011-06-01
Completion
2011-06-01
First posted
2011-07-07
Last updated
2018-11-01

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01389141. Inclusion in this directory is not an endorsement.